prasugrel or ticagrelor

Prasugrel and ticagrelor are both oral antiplatelet agents classified as P2Y12 receptor inhibitors. They are used to reduce the risk of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS), particularly those undergoing percutaneous coronary intervention (PCI). Both drugs act by inhibiting the P2Y12 component of ADP receptors on platelet surfaces, thereby preventing platelet activation and aggregation. Prasugrel is a thienopyridine prodrug that requires hepatic activation, while ticagrelor is a cyclopentyltriazolopyrimidine that acts directly without metabolic activation. Both have demonstrated superior efficacy compared to clopidogrel in reducing ischemic events but carry an increased risk of bleeding[6][8][9]. Clinical trials and real-world studies suggest similar overall efficacy between the two drugs; however, some data indicate prasugrel may be associated with lower rates of myocardial infarction and stent thrombosis compared to ticagrelor in certain ACS populations[5][7][10].

Brand names

EffientBrilinta